“Combining the 31-gene expression profile test for cutaneous melanoma with the American Joint Committee on Cancer staging identifies the highest-risk patients with stage I-II disease” (2023) SKIN The Journal of Cutaneous Medicine, 7(4), p. s223. doi:10.25251/skin.7.supp.223.